Allergan has received a license from the European Commission to market its Ganfort product in the European Union. Ganfort is meant to be used to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension who cannot get a significant response from topical beta-blockers or prostaglandin analogues.
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
To continue reading this article register now.